Phase 2 Pancreatic Cancer Trial, Recruiting NCT07529483 Sponsor: Ohio State University Comprehensive Cancer Center Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07529483
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have been diagnosed with a pancreatic cyst (a fluid-filled growth on the pancreas) confirmed through specialist procedures that examine the cyst using ultrasound, fluid sampling, or tissue analysis
  • People whose pancreatic cyst measures at least 1 cm across, as seen on a CT scan, MRI, or ultrasound
  • People who have previously had other treatments for their pancreatic cyst (such as radiofrequency ablation or pulsed electric field treatment) but whose cyst either did not respond or only partially responded to that treatment
  • People who are not suitable candidates for surgery — common reasons include liver cirrhosis, being 75 years or older, severe obesity, significant heart or lung conditions, other serious health conditions that make surgery too risky, or a personal preference to avoid surgery
  • People with an estimated life expectancy of at least one year
  • People who are able to give written consent themselves, or who have a legally authorised representative able to consent on their behalf
  • Women who could become pregnant must have a negative pregnancy test (blood or urine) on the day of the procedure, which is standard practice for all patients undergoing this type of procedure

Who may not be able to join:

  • People with severe or uncontrolled serious illnesses, or blood test results that the trial doctor considers too unsafe for participation
  • People with a psychiatric condition that makes it impossible to reliably understand and agree to what the trial involves
  • People who are currently pregnant or breastfeeding
  • People for whom general anaesthesia is not considered safe, based on an assessment by the pre-operative clinic at the trial site
  • People who do not speak English, as all study materials, consent forms, and patient questionnaires are currently available in English only, and the trial site has determined that interpreter-assisted consent may not adequately convey the risks of this investigational procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Somashekar G Krishna, MD, MPH, Ohio State University Comprehensive Cancer Center

Phone: 800-293-5066

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ohio State University Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
12 May 2026
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with greater than 90% reduction in cyst volume; Number of participants with > 50% to < 90% reduction in cyst volume; Number of participants with < 50% reduction in cyst volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov